Acadia Pharmaceuticals Inc. (ACAD)

$14.75

-0.55

(-3.59%)▲

Live

Performance

  • $14.74
    $15.53
    $14.75
    downward going graph

    0.1%

    Downside

    Day's Volatility :5.12%

    Upside

    5.02%

    downward going graph
  • $14.31
    $32.59
    $14.75
    downward going graph

    2.95%

    Downside

    52 Weeks Volatility :56.08%

    Upside

    54.74%

    downward going graph

Returns

PeriodAcadia Pharmaceuticals Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-15.61%
3.6%
0.0%
6 Months
-9.95%
10.2%
0.0%
1 Year
-31.33%
19.6%
0.0%
3 Years
-15.24%
16.8%
-23.0%

Highlights

Market Capitalization
2.5B
Book Value
$3.12
Earnings Per Share (EPS)
0.19
PE Ratio
79.84
PEG Ratio
-0.42
Wall Street Target Price
25.28
Profit Margin
3.43%
Operating Margin TTM
12.58%
Return On Assets TTM
1.83%
Return On Equity TTM
6.7%
Revenue TTM
890.5M
Revenue Per Share TTM
5.4
Quarterly Revenue Growth YOY
46.400000000000006%
Gross Profit TTM
145.5M
EBITDA
34.3M
Diluted Eps TTM
0.19
Quarterly Earnings Growth YOY
28.35
EPS Estimate Current Year
0.51
EPS Estimate Next Year
0.81
EPS Estimate Current Quarter
0.18
EPS Estimate Next Quarter
0.18

Analyst Recommendation

Buy
    73%Buy
    23%Hold
    3%Sell
Based on 26 Wall street analysts offering stock ratings for Acadia Pharmaceuticals Inc.(by analysts ranked 0 to 5 stars)
Based on 26 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
19
19
20
Hold
6
7
6
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 71.39%

Current $14.75
Target $25.28

Company Financials

FY18Y/Y Change
Revenue
223.8M
↑ 79.19%
Net Income
-245.2M
↓ 15.28%
Net Profit Margin
-109.56%
↑ 122.15%
FY19Y/Y Change
Revenue
339.1M
↑ 51.5%
Net Income
-235.3M
↓ 4.05%
Net Profit Margin
-69.38%
↑ 40.18%
FY20Y/Y Change
Revenue
441.8M
↑ 30.28%
Net Income
-281.6M
↑ 19.69%
Net Profit Margin
-63.74%
↑ 5.64%
FY21Y/Y Change
Revenue
484.1M
↑ 9.6%
Net Income
-167.9M
↓ 40.38%
Net Profit Margin
-34.67%
↑ 29.07%
FY22Y/Y Change
Revenue
517.2M
↑ 6.83%
Net Income
-216.0M
↑ 28.66%
Net Profit Margin
-41.76%
↓ 7.09%
FY23Y/Y Change
Revenue
726.4M
↑ 40.45%
Net Income
-61.3M
↓ 71.62%
Net Profit Margin
-8.44%
↑ 33.32%
Q1 FY23Q/Q Change
Revenue
118.5M
↓ 13.21%
Net Income
-43.0M
↑ 3.11%
Net Profit Margin
-36.32%
↓ 5.75%
Q2 FY23Q/Q Change
Revenue
165.2M
↑ 39.48%
Net Income
1.1M
↓ 102.59%
Net Profit Margin
0.67%
↑ 36.99%
Q3 FY23Q/Q Change
Revenue
211.7M
↑ 28.12%
Net Income
-65.2M
↓ 5950.63%
Net Profit Margin
-30.79%
↓ 31.46%
Q4 FY23Q/Q Change
Revenue
231.0M
↑ 9.14%
Net Income
45.8M
↓ 170.27%
Net Profit Margin
19.82%
↑ 50.61%
Q1 FY24Q/Q Change
Revenue
205.8M
↓ 10.91%
Net Income
16.6M
↓ 63.85%
Net Profit Margin
8.04%
↓ 11.78%
Q2 FY24Q/Q Change
Revenue
242.0M
↑ 17.55%
Net Income
33.4M
↑ 101.69%
Net Profit Margin
13.8%
↑ 5.76%
FY18Y/Y Change
Total Assets
540.2M
↑ 40.49%
Total Liabilities
61.1M
↑ 24.18%
FY19Y/Y Change
Total Assets
783.2M
↑ 44.98%
Total Liabilities
84.0M
↑ 37.51%
FY20Y/Y Change
Total Assets
782.6M
↓ 0.07%
Total Liabilities
155.6M
↑ 85.14%
FY21Y/Y Change
Total Assets
700.1M
↓ 10.54%
Total Liabilities
159.2M
↑ 2.33%
FY22Y/Y Change
Total Assets
587.8M
↓ 16.04%
Total Liabilities
187.4M
↑ 17.69%
FY23Y/Y Change
Total Assets
749.0M
↑ 27.41%
Total Liabilities
317.2M
↑ 69.27%
Q1 FY23Q/Q Change
Total Assets
655.3M
↑ 11.48%
Total Liabilities
281.0M
↑ 49.97%
Q2 FY23Q/Q Change
Total Assets
642.8M
↓ 1.91%
Total Liabilities
247.0M
↓ 12.12%
Q3 FY23Q/Q Change
Total Assets
632.5M
↓ 1.59%
Total Liabilities
270.4M
↑ 9.47%
Q4 FY23Q/Q Change
Total Assets
749.0M
↑ 18.4%
Total Liabilities
317.2M
↑ 17.32%
Q1 FY24Q/Q Change
Total Assets
855.1M
↑ 14.17%
Total Liabilities
391.1M
↑ 23.28%
Q2 FY24Q/Q Change
Total Assets
914.1M
↑ 6.9%
Total Liabilities
397.4M
↑ 1.62%
FY18Y/Y Change
Operating Cash Flow
-167.5M
↓ 23.13%
Investing Cash Flow
-71.5M
↓ 177.31%
Financing Cash Flow
306.6M
↑ 883.22%
FY19Y/Y Change
Operating Cash Flow
-151.1M
↓ 9.76%
Investing Cash Flow
-165.8M
↑ 131.97%
Financing Cash Flow
371.8M
↑ 21.26%
FY20Y/Y Change
Operating Cash Flow
-136.2M
↓ 9.9%
Investing Cash Flow
192.5M
↓ 216.08%
Financing Cash Flow
81.0M
↓ 78.22%
FY21Y/Y Change
Operating Cash Flow
-125.7M
↓ 7.72%
Investing Cash Flow
-71.1M
↓ 136.93%
Financing Cash Flow
18.2M
↓ 77.58%
FY22Y/Y Change
Operating Cash Flow
-114.0M
↓ 9.25%
Investing Cash Flow
73.2M
↓ 203.01%
Financing Cash Flow
8.2M
↓ 54.86%
Q1 FY23Q/Q Change
Operating Cash Flow
-17.9M
↓ 24.82%
Investing Cash Flow
192.5M
↓ 1184.73%
Financing Cash Flow
1.5M
↓ 9.17%
Q2 FY23Q/Q Change
Operating Cash Flow
8.2M
↓ 145.73%
Investing Cash Flow
-194.3M
↓ 200.92%
Financing Cash Flow
5.5M
↑ 273.67%
Q3 FY23Q/Q Change
Operating Cash Flow
-59.0M
↓ 818.88%
Investing Cash Flow
34.1M
↓ 117.56%
Financing Cash Flow
12.8M
↑ 132.77%

Technicals Summary

Sell

Neutral

Buy

Acadia Pharmaceuticals Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.
-6.08%
-9.95%
-31.33%
-15.24%
-64.62%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.
79.84
79.84
-0.42
0.51
0.07
0.02
NA
3.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.
Buy
$2.5B
-64.62%
79.84
3.43%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Acadia Pharmaceuticals Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 205.83M → 241.96M (in $), with an average increase of 14.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 16.55M → 33.38M (in $), with an average increase of 50.4% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 113.9%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 60.0%

Institutional Holdings

  • Baker Bros Advisors LP

    25.85%

  • Vanguard Group Inc

    8.27%

  • RTW INVESTMENTS, LLC

    8.26%

  • BlackRock Inc

    7.27%

  • State Street Corp

    3.50%

  • Point72 Asset Management, L.P.

    2.24%

Company Information

acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies

Organization
Acadia Pharmaceuticals Inc.
Employees
630
CEO
Mr. Mark C. Schneyer
Industry
Health Technology

Discover More

FAQs